Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Cash: 2021-2025

Historic Change in Cash for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $38.8 million.

  • Krystal Biotech's Change in Cash rose 37.60% to $38.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year increase of 2470.76%. This contributed to the annual value of -$13.5 million for FY2024, which is 106.85% down from last year.
  • Latest data reveals that Krystal Biotech reported Change in Cash of $38.8 million as of Q3 2025, which was down 13.95% from $45.1 million recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's Change in Cash peaked at $135.1 million during Q2 2023, and registered a low of -$72.6 million during Q2 2021.
  • Its 3-year average for Change in Cash is $21.0 million, with a median of $678,000 in 2024.
  • Within the past 5 years, the most significant YoY rise in Krystal Biotech's Change in Cash was 440.84% (2025), while the steepest drop was 5,423.75% (2025).
  • Krystal Biotech's Change in Cash (Quarterly) stood at $54.6 million in 2021, then crashed by 144.86% to -$24.5 million in 2022, then spiked by 39.15% to -$14.9 million in 2023, then plummeted by 95.14% to -$29.1 million in 2024, then spiked by 37.60% to $38.8 million in 2025.
  • Its last three reported values are $38.8 million in Q3 2025, $45.1 million for Q2 2025, and -$36.1 million during Q1 2025.